Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Fibronectin glomerulopathy

Brad H Rovin, MD
Section Editors
Richard J Glassock, MD, MACP
Fernando C Fervenza, MD, PhD
Deputy Editor
Albert Q Lam, MD


Several glomerular disorders result from the deposition or accumulation of proteins within glomeruli that disrupt glomerular structure and function. One of these disorders is fibronectin glomerulopathy, which is a rare, familial glomerular disease caused by the deposition of fibronectin and other matrix-type proteins in glomeruli. Ultrastructurally, the deposits are electron-dense and usually homogenous to finely granular, occasionally showing fibrillar substructure.

Fibronectin glomerulopathy will be reviewed here. Other glomerular disorders resulting from the deposition or accumulation of proteins within glomeruli, including amyloidosis, fibrillary glomerulonephritis, immunotactoid glomerulonephritis, and lipoprotein glomerulopathy, are presented in detail elsewhere. (See "Renal amyloidosis" and "Glomerular diseases due to nonamyloid fibrillar deposits" and "Lipoprotein glomerulopathy".)


Biology of fibronectin — Fibronectin is a large dimeric glycoprotein consisting of two similar subunits (approximately 250 kD in weight). It functions as an adhesive glycoprotein, aiding in branching morphogenesis, cellular proliferation, wound healing, phagocytosis, platelet-platelet cohesion that is mediated in part by binding to the glycoprotein IIb/IIIa receptor, and thrombus formation [1-3].

Fibronectin normally exists in a soluble or plasma form (which circulates in blood) and an insoluble or cellular form (which is seen in basement membranes and extracellular matrices).

Fibronectin deposition — Although fibronectin is found in the normal glomerular mesangial matrix, enhanced fibronectin accumulation is variably observed in several different glomerulopathies, including diabetic nephropathy and lupus nephritis [4-11]. The increase in fibronectin expression in these diseases is secondary to locally stimulated mesangial and epithelial cell production of the insoluble or cellular form.


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Jul 5, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Sakai T, Larsen M, Yamada KM. Fibronectin requirement in branching morphogenesis. Nature 2003; 423:876.
  2. Ni H, Yuen PS, Papalia JM, et al. Plasma fibronectin promotes thrombus growth and stability in injured arterioles. Proc Natl Acad Sci U S A 2003; 100:2415.
  3. Schena FP, Pertosa G. Fibronectin and the kidney. Nephron 1988; 48:177.
  4. Büyükbabani N, Droz D. Distribution of the extracellular matrix components in human glomerular lesions. J Pathol 1994; 172:199.
  5. Altunkova I, Minkova V, Belovezhdov N. Role of fibronectin in immune glomerulonephritis. Nephron 1993; 63:438.
  6. Lai KN, To WY, Leung JC, et al. Serologic study of immunoglobulin A-fibronectin aggregates in immunoglobulin A nephropathy. Am J Kidney Dis 1996; 27:622.
  7. Shikata K, Makino H, Morioka S, et al. Distribution of extracellular matrix receptors in various forms of glomerulonephritis. Am J Kidney Dis 1995; 25:680.
  8. Van Vliet A, Baelde HJ, Vleming LJ, et al. Distribution of fibronectin isoforms in human renal disease. J Pathol 2001; 193:256.
  9. Zhao HL, Lai FM, Tong PC, et al. Clinicopathologic characteristics of nodular glomerulosclerosis in Chinese patients with type 2 diabetes. Am J Kidney Dis 2004; 44:1039.
  10. Ding L, Zhao M, Zou W, et al. Mycophenolate mofetil combined with prednisone for diffuse proliferative lupus nephritis: a histopathological study. Lupus 2004; 13:113.
  11. Oomura A, Nakamura T, Arakawa M, et al. Alterations in the extracellular matrix components in human glomerular diseases. Virchows Arch A Pathol Anat Histopathol 1989; 415:151.
  12. Strøm EH, Banfi G, Krapf R, et al. Glomerulopathy associated with predominant fibronectin deposits: a newly recognized hereditary disease. Kidney Int 1995; 48:163.
  13. Otsuka Y, Takeda A, Horike K, et al. A recurrent fibronectin glomerulopathy in a renal transplant patient: a case report. Clin Transplant 2012; 26 Suppl 24:58.
  14. Gemperle O, Neuweiler J, Reutter FW, et al. Familial glomerulopathy with giant fibrillar (fibronectin-positive) deposits: 15-year follow-up in a large kindred. Am J Kidney Dis 1996; 28:668.
  15. Tuttle SE, Sharma HM, Bay W, Hebert L. A unique familial lobular glomerulopathy. Arch Pathol Lab Med 1987; 111:726.
  16. Satoskar AA, Shapiro JP, Bott CN, et al. Characterization of glomerular diseases using proteomic analysis of laser capture microdissected glomeruli. Mod Pathol 2012; 25:709.
  17. Twal WO, Czirok A, Hegedus B, et al. Fibulin-1 suppression of fibronectin-regulated cell adhesion and motility. J Cell Sci 2001; 114:4587.
  18. Lomas AC, Mellody KT, Freeman LJ, et al. Fibulin-5 binds human smooth-muscle cells through alpha5beta1 and alpha4beta1 integrins, but does not support receptor activation. Biochem J 2007; 405:417.
  19. Castelletti F, Donadelli R, Banterla F, et al. Mutations in FN1 cause glomerulopathy with fibronectin deposits. Proc Natl Acad Sci U S A 2008; 105:2538.
  20. Ertoy Baydar D, Kutlugun AA, Bresin E, Piras R. A case of familial glomerulopathy with fibronectin deposits caused by the Y973C mutation in fibronectin. Am J Kidney Dis 2013; 61:514.
  21. Ohtsubo H, Okada T, Nozu K, et al. Identification of mutations in FN1 leading to glomerulopathy with fibronectin deposits. Pediatr Nephrol 2016; 31:1459.
  22. Zhang Z, Kundu GC, Yuan CJ, et al. Severe fibronectin-deposit renal glomerular disease in mice lacking uteroglobin. Science 1997; 276:1408.
  23. Mukherjee AB, Kundu GC, Mandal AK, et al. Uteroglobin: physiological role in normal glomerular function uncovered by targeted disruption of the uteroglobin gene in mice. Am J Kidney Dis 1998; 32:1106.
  24. Vollmer M, Krapf R, Hildebrandt F. Exclusion of the uteroglobin gene as a candidate for fibronectin glomerulopathy (GFND). Nephrol Dial Transplant 1998; 13:2417.
  25. Hildebrandt F, Strahm B, Prochoroff A, et al. Glomerulopathy associated with predominant fibronectin deposits: exclusion of the genes for fibronectin, villin and desmin as causative genes. Am J Med Genet 1996; 63:323.
  26. Chen H, Bao H, Xu F, et al. Clinical and morphological features of fibronectin glomerulopathy: a report of ten patients from a single institution. Clin Nephrol 2015; 83:93.
  27. Ishimoto I, Sohara E, Ito E, et al. Fibronectin glomerulopathy. Clin Kidney J 2013; 6:513.
  28. Bürgin M, Hofmann E, Reutter FW, et al. Familial glomerulopathy with giant fibrillar deposits. Virchows Arch A Pathol Anat Histol 1980; 388:313.
  29. Assmann KJ, Koene RA, Wetzels JF. Familial glomerulonephritis characterized by massive deposits of fibronectin. Am J Kidney Dis 1995; 25:781.
  30. Sanders PW. Dysproteinemias and amyloidosis. In: Primer of Kidney Diseases, 2nd ed, Greenberg A, Cheung AK, Coffmann TM, et al (Eds), Academic Press, San Diego 1998. p.220.